| 000 | 03111nam a22004455i 4500 | ||
|---|---|---|---|
| 999 |
_c368026 _d368026 _x1 |
||
| 001 | 368026 | ||
| 003 | ES-MaUEC | ||
| 005 | 20230102121659.0 | ||
| 006 | a||||fo|||| 00| 0 | ||
| 007 | cr nn 008mamaa | ||
| 008 | 220131s2022 sz | s |||| 0|eng d | ||
| 020 | _a9783030860769 | ||
| 024 | 7 |
_a10.1007/978-3-030-86076-9 _2doi |
|
| 040 |
_aES-MaUEC _bspa _cES-MaUEC _dES-MaUEC |
||
| 050 | 4 |
_aRC46 _b2022 EB |
|
| 245 | 1 | 0 |
_aPrevention and Treatment of Atherosclerosis : _bImproving State-of-the-Art Management and Search for Novel Targets _cedited by Arnold von Eckardstein, Christoph J. Binder. |
| 250 | _aFirst edition 2022 | ||
| 264 | 1 |
_aCham _bSpringer International Publishing _c2022 |
|
| 300 |
_a1 recurso en línea (X, 538 páginas) _b40 ilustraciones, 37 ilustraciones a color |
||
| 336 |
_2rdacontent _aTexto _btxt |
||
| 337 |
_2rdamedia _aelectrónico _bc |
||
| 338 |
_2rdacarrier _arecurso electrónico _bcr |
||
| 347 |
_aarchivo de texto _bPDF |
||
| 490 | 0 |
_aHandbook of Experimental Pharmacology _x1865-0325 _v270 |
|
| 505 | 0 | _aDiet, Life Style, Smoking -- Blood Pressure Lowering -- Glycemic Control in Diabetes -- LDL-Cholesterol Lowering -- Antithrombotic Therapy (Platelet Inhibition, Anti-coagulation) -- Triglyceride Rich Lipoproteins -- HDL -- Lipoprotein(a) -- Obesity, Non-alcoholic Fatty Liver Disease, and Metabolic Syndrome -- Nutraceuticals / Functional Food -- Adipose Tissue (WAT, BAT) -- Microbiota and Cardiometabolic Disease -- SMCs, Matrix -- Immune Modulation -- NETs and Neutrophils -- Genomic Strategies Towards Identification of Novel Therapeutic Targets -- Non Coding RNAs -- Metabolomics, Lipidomics -- Epigenomics. | |
| 506 | 0 | _aOpen Access | |
| 520 | _aThis open access book is supported by the European Atherosclerosis Society Association (EAS). This follow-up edition of the well-received Handbook volume 'Atherosclerosis: Diet and Drugs' reflects the state-of-the-art and most recent developments in atherosclerosis research. Outstanding international experts give a comprehensive overview of the field covering topics, such as improving the treatment focusing on established targets, novel drug developments addressing pre-defined targets, hypothesis-based and hypothesis-free approaches to unravel novel targets. . | ||
| 988 | _aSpringer_BiomedLife_2022 | ||
| 650 | 7 |
_2embne _aMedicina interna _9138387 |
|
| 700 |
_avon Eckardstein, Arnold _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt _993586 |
||
| 700 |
_aBinder, Christoph J. _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt _9683402 |
||
| 776 | 0 | 8 |
_iPrinted edition: _z9783030860752 |
| 776 | 0 | 8 |
_iPrinted edition: _z9783030860776 |
| 776 | 0 | 8 |
_iPrinted edition: _z9783030860783 |
| 856 | 4 | 0 |
_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-030-86076-9 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid) |
| 942 |
_2lcc _cLE _n0 |
||
| 998 |
_b04/2022 _dz _ep _zSI |
||